Abstract Number: 1395 • 2012 ACR/ARHP Annual Meeting
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Background/Purpose: SLE is a chronic autoimmune disease with variable manifestations. New developments in the understanding and treatment of SLE mandated closer monitoring of the disease…Abstract Number: 1356 • 2012 ACR/ARHP Annual Meeting
Gender Differences Among Spondylitis Associated with Psoriasis, Inflammatory Bowel Disease and Primary Ankylosing Spondylitis
Background/Purpose: Differences regarding gender in primary Ankylosing Spondylitis are well known. However, there is less evidence regarding Spondylitis Associated with Psoriasis and that associated with…Abstract Number: 1357 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis and Biologic Therapy: Treatment Response, Drug Survival and Outcome After Switching
Background/Purpose: Data on longer term efficacy and tolerance of biologic therapies in psoriatic arthritis (PsA) are emerging. Persistence with the first TNF inhibitor (TNFi) at…Abstract Number: 1358 • 2012 ACR/ARHP Annual Meeting
Performance of Remission Criteria and Activity Indices in Psoriatic Arthritis
Background/Purpose: Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Although indices have been specifically developed for…Abstract Number: 1359 • 2012 ACR/ARHP Annual Meeting
Comparison of Sacroiliac MRI Evaluation Versus Sacroiliac x-Rays in Peripheral Psoriatic Arthritis: Evidence of Silent Disease and Lack of Association to HLA-B27
Background/Purpose: Although there are no consensus on how to define spinal involvement in axial psoriatic artritis (axPsA), our data suggest that the presence of spinal…Abstract Number: 1360 • 2012 ACR/ARHP Annual Meeting
Spinal Involvement in Axial Psoriatic Artritis Is Not Determined by the Presence of HLA-B27. Is the HLA-B27 Arm of the Axial Spa Criteria Reliable for Classifying Axial Psoriatic Arthritis?
Background/Purpose: There is a debate whether axial psoriatic arthritis (axPsA) is an ankylosing spondylitis with psoriasis, however due to the fact that PsA has characteristic…Abstract Number: 1361 • 2012 ACR/ARHP Annual Meeting
Disease Burden Is Comparable in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
Background/Purpose: Chronic back pain and functional impairment are disease characteristics common to all patients (pts) with axial spondyloarthritis (SpA), regardless of the presence of radiographic…Abstract Number: 1362 • 2012 ACR/ARHP Annual Meeting
Evaluation of Spondyloarthritis activity by the Patients and the Physicians: ASDAS, Basdai, PASS and Flare
Background/Purpose: Objectives: to define thresholds of the ASDAS corresponding to the PASS (Pateint Acceptable Symptomatic State) and to the thresholds of activity of the disease…Abstract Number: 1363 • 2012 ACR/ARHP Annual Meeting
Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Background/Purpose: Comorbidities can importantly influence the results of clinical studies on functional outcomes as they may act as confounders or effect modifiers. The generic self-administered…Abstract Number: 1364 • 2012 ACR/ARHP Annual Meeting
Development, Sensibility and Reliability of a New Case-Finding Questionnaire, the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease
Background/Purpose: Inflammatory bowel disease (IBD) encompasses Crohn's disease, ulcerative colitis, and indeterminate colitis. Articular involvement [(peripheral arthritis and axial spondyloarthritis (axSpA)] is the most common…Abstract Number: 1365 • 2012 ACR/ARHP Annual Meeting
Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Background/Purpose: Efficacy of anti–tumor necrosis factor (TNF) therapy in patients with axial spondyloarthritis (SpA) has been tested only in patients who are refractory to NSAIDs.…Abstract Number: 1366 • 2012 ACR/ARHP Annual Meeting
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo-Controlled StudyBackground/Purpose: This…Abstract Number: 1367 • 2012 ACR/ARHP Annual Meeting
Clinical Features and Treatment Results of Japanese Patients with SAPHO (Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis) Syndrome
Background/Purpose: SAPHO syndrome is a disorder characterized by pustular skin lesions and osteoarticular lesions, which was proposed by Chamot et al. in 1987. Clinical studies…Abstract Number: 1368 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis in South Asians- Comparison with Caucasians of European Descent
Background/Purpose: The prevalence of psoriatic arthritis (PsA) varies substantially world-wideand is highest among Caucasians of European descent. Studies from India suggest that patients with PsA…Abstract Number: 1369 • 2012 ACR/ARHP Annual Meeting
Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis
Background/Purpose: Patients with Psoriatic arthritis (PsA) who develop severe joint damage have severe functional disability and increased mortality risk. The most severe form of PsA…